Delix Announces DLX-001 Demonstrates Evidence of CNS Penetration and Brain Activity Without Psychotomimetic, Dissociative, or Hallucinogenic Effects in Ongoing Phase 1 Trial
The Company also announced preclinical data showing the effects of DLX-001 on antidepressant, structural, and functional plasticity assays.
- The Company also announced preclinical data showing the effects of DLX-001 on antidepressant, structural, and functional plasticity assays.
- Part B is an open-label crossover design study to investigate the effect of food on the PK of DLX-001.
- No psychotomimetic, hallucinatory, or dissociative effects have been observed, as reflected by no change over time on a robust battery of assessments.
- DLX-001 exhibited both rapid—within 24-hours, and enduring—up to 14 days, antidepressant-like activity after a single dose in multiple behavioral models.